The top three most differentially targeted BTMs were LI.M161.0 (enriched in NK cells (II)), LI.M43.0 (myeloid, dendritic cell activation via NFkB), and LI.M7.2 (growth factor induced, enriched in nuclear receptor subfamily), all of which exhibited weakened regulation in the HD group. This evidence concerns the gene NFKB1 and Huntington disease.